Market research
ARX.AU Aroa Biosurgery Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 200M
- P/E ratio
- 57.0
- Analyst target
- 1.0893
- Dividend yield
- Not available
- Beta
- 0.85
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- NZARXE0001S1
- Market cap
- 200M
- P/E ratio
- 57.0
- Analyst target
- 1.0893
- Dividend yield
- Not available
- Beta
- 0.85
About
About Aroa Biosurgery Limited
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symphony products for the treatment of partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ARX.AU discussion.
5 years, 5 months ago
Aroa Biosurgery Limited is currently in a long term uptrend where the price is trading 3.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Aroa Biosurgery Limited's total revenue sank by 30.3% to $9M since the same quarter in the previous year.
Its net income has dropped by 1440.3% to $-13M since the same quarter in the previous year.
Finally, its free cash flow fell by 240.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Aroa Biosurgery Limited gets an overall score of 2/5.